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Thyroparathyroidectomy modifies the skeletal response to aluminum
loading in the rat. Diminished parathyroid hormone (PTH) secretion
may contribute to the accumulation of aluminum (Al) in bone and to
impaired bone formation in Al-related bone disease. Therefore, intact
(AL, N = 9) and thyroparathyroidectomized (TPTX-AL, N = 9) rats
were given intraperitoneal injections of Al, 2 mg/day, for 42 days; intact
control (C, N = 11) and TPTX control (TPTX-C, N = 9) animals
received i.p. injections of vehicle only. Quantitative bone histology and
measurements of mineralized bone formation (Rbf) using double tetra-
cycline labeling were done for cortical and for trabecular bone;
trabecular bone aluminum content (BA) was determined by histochem-
ical methods. BA did not differ between AL and TPTX-AL, 33 13%
versus 39 14%, and Rbf decreased similarly from control values in
both Al-treated groups. In contrast, osteoid production was impaired to
a greater extent in TPTX-AL than in AL. Thus, osteoid area and
osteoid seam width were each lower in TPTX-AL than in TPTX-C;
these values did not differ between AL and C. TPTX can aggravate Al
induced reductions in osteoid synthesis, and low serum PTH levels may
contribute to the pathogenesis of aplastic bone. However, reductions in
Rbf during Al loading are not mediated by PTH.
Aluminum—related bone disease can occur in patients with
chronic renal failure and in those with normal renal function
exposed to aluminum through parenteral sources [1—7]. The
pathogenesis of this disorder remains to be established, but the
results of several clinical and experimental studies suggest that
the toxicity of aluminum on bone may be direct [7—111. Thus,
the aluminum content of bone correlates with the histologic
severity of osteomalacia in dialysis patients with aluminum—re-
lated bone disease [6, 81, and the bone aluminum content is
inversely related to the rate of bone formation in this disorder
[6, 7]. Although these observations are consistent with a direct
adverse effect of aluminum on the skeleton, aluminum may also
indirectly suppress the biosynthesis of bone collagen and/or
impede skeletal mineralization by altering one or several hor-
monal factors that modify these two processes.
The serum levels of immunoreactive parathyroid hormone
(P1'H) are often normal or only moderately increased in dialysis
patients with aluminum—related bone disease [12]. Several
investigators have demonstrated that the secretion of PTH in
Received for publication March 19, 1986
and in revised form July 14 and October 10, 1986
© 1987 by the International Society of Nephrology
response to hypocalcemia is diminished in hemodialysis pa-
tients with aluminum associated osteomalacia [13, 14]. These
observations suggest that the function of the parathyroid glands
is impaired in this disorder. Moreover, the rate of aluminum
accumulation in bone accelerates following parathyroidectomy
in long—term hemodialysis patients [15], and the development of
clinically severe osteomalacia with evidence of aluminum dep-
osition in bone has been noted after surgical parathyroidectomy
in patients undergoing chronic hemodialysis [16]. Thus, either
reductions in the secretion of PTH from previously high levels
or persistently—low serum levels of PTH may modify the
deposition of aluminum in bone, or its toxicity, and contribute
to the development of aluminum—related bone disease.
To study this issue, the effect of persistently—low serum
levels of PTH on the skeletal response to six weeks of paren-
teral aluminum administration was evaluated in pair—fed intact
and thyroparathyroidectomized (TPTX) rats given daily injec-
tions of either aluminum or saline vehicle. Quantitative bone
histology and measurements of bone formation were done for
all animals. Bone formation decreased both in intact and in
TPTX rats given equal amounts of aluminum, but the percent
reduction from control values was similar for each group. The
deposition of aluminum in bone was not enhanced by thyro-
parathyroidectomy, and neither group of aluminum treated rats
developed osteomalacia. In contrast, histologic changes of
aplastic bone were documented in TPTX aluminum—loaded
animals but not in parathyroid—intact animals given aluminum.
Methods
Experimental protocol
Weanling male Holtzman rats (Holtzman Co., Madison,
Wisconsin, USA) were obtained at three weeks of age, housed
in individual suspended—wire cages with free access to water,
and maintained on a diet that contained 0.6% calcium and 0.6%
phosphorus for the duration of study [17, 18]. One—half of the
animals underwent thyroparathyroidectomy (TPTX) five days
before the start of the experiment. TPTX was done by blunt
dissection under pentobarbital anesthesia, 20 mg/kg, and serum
calcium concentrations were measured before and 48 hours
after surgery [19]. A decrement in the serum calcium concen-
tration of 2 mgldl or greater from pre-operative levels was taken
as evidence of successful extirpation of the parathyroid glands
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[191. Thyroxine, 0.1 g/100 g body weight, was given by daily
subcutaneous injections to TPTX rats beginning on the second
day after surgery; these were continued until completion of the
study.
Thyroparathyroidectomized rats were matched by weight
and assigned to either a control (TPTX-C, N = 9) or an
aluminum treated (TPTX-AL, N = 9) group. Intact, non-TPTX
animals were also matched by weight and assigned to either a
control (C, N = 11) or an aluminum treated (AL, N = 9) group.
To maintain similar degrees of weight gain for animals in all four
groups, individual rats in C, AL, and TPTX-C were pair fed
with animals in TPTX-AL [17, 19].
Intraperitoneal (i.p.) injections of aluminum were given to
animals in AL and TPTX-AL five days each week for a total of
42 days; aluminum was administered as a solution containing
aluminum chloride, Aid3, in saline vehicle [17, 18]. The daily
dose of elemental aluminum was 2 mg/rat except during the first
five days of study when an incremental dose was given to avoid
the development of chemical peritonitis [17, 18]. The cumula-
tive dose of aluminum for rats in AL and TPTX-AL was 54.2
mg. Animals in C and TPTX-C received daily i.p. injections of
vehicle only.
All animals were given single i.p. injections of tetracycline
HC1, 20 mg/kg, eight days and one day before killing on day 42
at the conclusion of the experiment [17—19]. Rats were killed by
exsanguination by cardiac puncture while under pentobarbital
anesthesia, 40 mg/kg, and samples of serum were frozen for
subsequent biochemical determinations.
Bone measurements
After the animals were killed, the right tibia was removed,
stripped of adhering soft tissue, and placed in gauze saturated
with 10% formalin until sections of tissue were prepared for
histologic examination. Quantitative bone histology and mea-
surements of bone formation were determined for cortical and
for trabecular bone using methods outlined in detail elsewhere
[11, 17—20].
Cross sections of non-decalcified cortical bone were obtained
from the tibia! diaphysis at the fibular junction [17, 18]. These
were stained with nuclear fast red and examined by light
microscopy for histologic measurements and by fluorescence
microscopy for the evaluation of tetracycline labels [17, 18].
Sections of undecalcified trabecular bone from the epiphysis
of the right tibia were prepared after infiltrating the proximal
one—third of the tibia with glycol-methylmethacryiate and p0-
lymerizing the blocks under 100% carbon dioxide at 4°C. [11,
19, 20]. Frontal sections of the proximal tibia were made using
a sledge microtome (Jung Autocut Model 1140, Reichert—Jung,
Vienna, Austria) [11, 19, 20]. Five jtm sections of trabecular
bone were stained by the modified Goidner technique and
examined by light microscopy; ten m sections were mounted
unstained in 10% glycerol and viewed by fluorescence micros-
copy for the evaluation of tetracycline labels [11, 19, 20]. Five
jm sections were also stained by the aurine—tricarboxylic acid
method for histochemical determinations of the aluminum con-
tent of bone [11, 20, 21].
The quantitation of histological variables in sections of cor-
tical and trabecular bone was done using a digitizer interfaced
with a microcomputer as previously described [11, 17—20]. All
measurements of length, width, and area were determined
Table 1. Serum biochemistries, weight gains, and bone aluminum
content in intact and thyroparathyroidectomized rats given daily
injections of aluminum or vehiclea
C
N=11
ALN=9 TPTX-CN=9 TPTX-ALN=9
Serum calcium 9.7 9•5 60b 65b.C
mg/dl 0.2 0.7 0.9 0.8
Serum phosphorus 8,4 9.2 14•6b 139b,c
mg/dl 0.9 1.3 1.3 2.0
Weight gain 205.9 206.1 201.5 184.7
g 17.6 19.0 29.0 27.8
Bone aluminum content ND 33.1 ND 38.7
% of trabecular bone 13.3 14.4
surface
Values are means one SD. Probabilities determined by the f-test
for unpaired samples
b P < 0.001 vs. C
P < 0.001 vs. AL
ND, none detected
directly from projected images using a drawing tube and pro-jection prism attached to a Leitz Dialuz microscope (Leitz,
Wetzlar, FRG) [11, 17—201.
The following variables were determined for both cortical and
trabecular bone: 1) total bone area (%)—the area of bone,
including both mineralized bone and osteoid, expressed as a
percentage of the total tissue area; 2) osteoid area (%)—the area
of osteoid expressed as a percentage of the total bone area; 3)
osteoid seam width (m)—the mean width of osteoid seams; 4)
osteoid surface (%)—the percentage of bone surfaces covered
by osteoid seams; 5) resorption surface (%)—the percentage of
bone surfaces characterized by the presence of scalloped bone
resorptive lacunae; and 6) double tetracycline—labeled surface
(%)—the percentage of bone surfaces that exhibited double
bands of tetracycline fluorescence. The aluminum content of
bone was expressed as a percentage of the surface of trabecular
bone that stained for aluminum [11, 19, 20].
The rates of bone formation and bone apposition in the tibial
cortex were determined by methods outlined in detail elsewhere
[17, 181. For trabecular bone from the epiphysis, the rate of
mineralized bone apposition was calculated from measurements
of the width of separation of double tetracycline labels divided
by the time interval between the administration of the two
labels; the results are expressed in sm/day [11, 19]. The rate of
bone formation at the epiphysis was calculated by multiplying
the bone apposition rate by the length of double tetracy-
cline—labeled bone surface. These values represent the area of
new bone formed per unit area of existing trabecular bone per
day, and the results are expressed in mm2/mm2/day [11, 19].
Biochemical measurements
The concentrations of calcium in serum were determined by
atomic absorption spectroscopy [22]. Serum phosphorus levels
were measured using a micro-colorimetric method [23].
Statistical analysis
All values are expressed as the mean one standard devia-
tion. Statistical analysis of the data was done using the f-test for
unpaired samples, one—way analysis of variance with contrasts,
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Fig. 1. The rates of bone formation at the periosteal surface of the
tibia! cortex in control (C), aluminum treated (AL), TPTX control
(TPTX-C), and TPTX aluminum—treated (TPTX-AL) rats. Bone forma-
tion was measured over a seven day period using double tetracycline
labeling. Symbols are: (*) P < 0.001 vs. C; (t) P < 0.01 vs. C; (**) P <
0.01 vs. TPTX-C.
factorial analysis of variance with contrasts, and linear regres-
sion analysis [241.
Results
In both groups of thyroparathyroidectomized rats, serum
calcium concentrations were lower and serum phosphorus
concentrations were higher than in intact control animals (Table
1). There were no differences, however, between C and AL or
between TPTX-C and TPTX-AL in the values for serum cal-
cium or serum phosphorus (Table 1). Weight gains during the
experiment were similar for each study group (Table 1).
No aluminum was detected by histochemical staining in
sections of trabecular bone from either group of saline—injected
control rats. In contrast, all aluminum treated animals had
histochemical evidence of aluminum deposition in bone. Values
for the aluminum content of bone were similar, however, in AL
and TPTX-AL (Table 1).
Bone formation and mineralized bone apposition at the tibial
cortex decreased from control values in intact animals given
repeated injections of aluminum (Figs. 1 and 2). As expected,
the rates of bone formation and bone apposition were lower in
TPTX-C than in C, but each measurement was further reduced
in TPTX-AL (Figs. 1 and 2). Bone formation and mineralized
bone apposition decreased by 41% in AL and by 37% in
TPTX-AL; however, the percentage reduction from control
values for each variable was similar in the two aluminum—
treated groups (Figs. 1 and 2).
Consistent with data previously reported in TPTX rats, the
width of periosteal osteoid seams and the values for total
osteoid area in cortical bone were greater in TPTX control
animals than in intact controls (Table 2). Osteoid seam width
C
N= 11
AL
N=9 TPTX-CN=9 TPTX-ALN=9
Bone area 73.5 693d 743 7l.0
% of tissue area 3.6 3.2 4.2 4.7
Osteoid area 2.70 2.70 4.22" 2.98c
% of bone area 0.25 0.29 0.37 0.50
Osteoid seam width- 10.2 9.3 136b 10.3c
periostealiun 1.0 1.3 1.5 1.8
Osteoid surface 62.3 65.7 81.3" 72.6
% endosteal surface 8.9 7.0 9.3 14.0
Resorption surface 37.7 34.3 187b 27.4
% of endosteal surface 8.9 7.0 9.3 14.0
Double tetracycline label 62.3 65.7 81.3" 72.6
% endosteal surface 8.9 7.0 9.3 14.0
a Values are means one SD. Probabilities determined by the t-test
for unpaired samples except as indicatedb P < 0.001 vs. C
a P < 0.001 vs. TPTX-C
d P < 0.01 vs. C by analysis of variance with contrasts
P < 0.05 vs. TPTX-C by analysis of variance with contrasts
and total osteoid area remained similar in C and AL, but both
measurements decreased in TPTX-AL from the values deter-
mined in TPTX-C (Table 2). In TPTX-C, the results for
endosteal osteoid surface were higher and those for endosteal
resorption surface were lower than in C, but neither variable
differed substantially from control values in AL or in TPTX-AL
(Table 2). Total bone area decreased in each aluminum treated
group when compared to its respective control (Table 2).
Similar to the findings in cortical bone, mineralized bone
formation at the epiphysis of the proximal tibia was reduced
both in intact rats and in TPTX animals during aluminum
administration (Fig. 3). Bone formation fell by 41% in AL and
by 70% in TPTX-AL (Fig. 3). Although the values in TPTX-AL
were lower than those determined in the other three study
groups, P < 0.005 by factorial analysis of variance, the percent-
"4
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Fig. 2. The rates of mineralized bone apposition at the periosteal
surface of the tibial cortex in control (C), aluminum treated (AL), TPTX
control (TPTX-C), and TPTX aluminum—treated (TPTX-AL) rats. Bone
formation was measured as described in Figure 1. Symbols are: (*) P <
0.001 vs. C; (t) P < 0.01 vs. C; (**) P < 0.001 vs. TPTX-C.
Table 2. Quantitative histology of cortical bone in intact and
thyroparathyroidectomized rats given daily injections of aluminum
or vehiclea
C Al TPTX-C TPTX-AI
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Discussion
Table 3. Quantitative histology of trabecular bone in intact and
thyroparathyroidectomized rats given daily injections of
aluminum or vehiclea
C
N= 11
ALN=9 TPTX-CN=9 TPTX-ALN=9
Bone area 26.8 23,2b 26.3 22.4c
% of tissue area 3.2 4.3 2.8 4.5
Osteoid area 0.63 1.03 1.03" 0.25c
% of bone area 0.29 0.54 0.44 0.22
Osteoid seam width 4.4 5.2 5.1 3,71
xm 1.1 1.7 1.3 1.1
Osteoid surface 6.8 10.8 10.8 2,9
% of bone surface 4.1 7.6 5.3 2.7
Resorption surface 1.8 1.4 1.5 1.7
% of bone surface 0.7 0.5 0.9 1.3
Double tetracycline 13.9 8.3 11.6 34g
% of bone surface 1.2 6.3 5.4 3.2
SD. Probabilities determined by the i-test for
6
-c
a,
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0
a,
C Al TPTX-C TPTX-Al
Fig. 3. The rates of trabecular bone formation at the proximal tibial
epiphysis in control (C), aluminum treated (AL), TPTX control (TPTX-
C), and TPTX aluminum—treated (TPTX-AL) rats. Bone formation was
measured as described in Figure I. Symbols are: (*) P < 0.05 vs. C; (t)
P < 0.05 vs. C; (**) P < 0.01 vs. TPTX-C.
age reduction in bone formation did not differ in TPTX-AL and
AL.
The uptake of tetracycline at trabecular bone surfaces was
diminished in both groups of aluminum treated rats, and the
lowest values were again determined in TPTX-AL, P <0.01 by
factorial analysis of variance (Table 3). All rats in AL exhibited
double tetracycline labels in trabecular bone, but bone forma-
tion could not be measured in three animals from TPTX-AL
because double tetracycline labels were not identified. The
decrease in trabecular bone formation in aluminum treated
animals was due primarily to reductions in the extent of
tetracycline—labeled bone surface. Mineralized bone apposition
remained similar in C and AL, 1.47 0.14 versus 1.45 0.13
mIday, and in TPTX-C and TPTX-AL, 1.24 0,14 versus 1.06
0.21 xmlday. These findings in trabecular bone differed
substantially from the results obtained at the tibial cortex.
Neither group of aluminum treated rats demonstrated overt
histologic osteomalacia. Indeed, the area of osteoid in
trabecular bone was less in TPTX-AL than in each of the other
three groups (Table 3). The lower values for osteoid area in
TPTX-AL were due to reductions in the percentage of trabec-
ular bone surface covered with osteoid and to decreases in the
width of osteoid seams (Table 3). Also, trabecular bone area
decreased from control values in each group of aluminum
treated animals (Table 3).
The results of the current investigation indicate that persis-
tently low levels of PTH in serum can modify the skeletal
response to short—term aluminum administration in the rat.
Histologic features consistent with the aplastic lesion of renal
osteodystrophy were noted in cortical and trabecular bone in
TPTX aluminum—treated animals whereas these findings were
absent in pair fed, parathyroid intact rats given equal amounts
of aluminum. Bone formation was impaired and the area of
mineralized bone was decreased at cortical and at trabecular
sites within the skeleton in both groups of aluminum treated
animals. However, disproportionate reductions in bone forma-
tion could not be documented in TPTX-AL, and thyroparathy-
a Values are means
unpaired samples
b P < 0,01 vs. C by analysis of variance with contrasts
P < 0.01 vs. TPTX-C by analysis of variance with contrasts
"P < 0.05 vs. C
P < 0.001 vs. TPTX-C
1P < 0.05 vs. TPTX-C
g p < 0.01 vs. TPTX-C
roidectomy did not enhance the deposition of aluminum in
bone. These data suggest that the level of PTH in serum can
modify the histologic response of bone to aluminum adminis-
tration, but that reductions in the formation of mineralized bone
during aluminum loading are not related to PTH-mediated
changes in the skeletal uptake of aluminum.
Several reports indicate that parathyroidectomy may be a
risk factor for the development of aluminum—related bone
disease in patients undergoing long term dialysis [15, 161. The
data of Andress et al suggest that reductions in bone formation
and turnover following parathyroidectomy contribute to the
deposition of aluminum at the surface of bone and to the
subsequent development of aluminum—related bone disease
[15]. Norris et al noted a higher prevalence of previous para-
thyroidectomy in dialysis patients with biopsy proven,
aluminum—related bone disease when compared to a control
group of dialysis subjects referred for clinical and bone biopsy
evaluations of renal osteodystrophy [25].
Despite such observations from clinical bone—biopsy mate-
rial, thyroparathyroidectomy did not increase the deposition of
aluminum in bone in the current short term study. The percent-
age of trabecular bone surfaces that stained for aluminum by
histochemical methods was similar in intact and in TPTX rats.
Measurements of the tissue content of aluminum using flame-
less atomic absorption spectroscopy were not done, and this
technique may have detected small differences in the aluminum
content of bone between AL and TPTX-AL. However, the
histochemical stain for bone aluminum determinations has
previously been of value for the quantitation of differences in
the extent of aluminum deposition in bone, both in subtotally
nephrectomized rats and in rats with normal renal function
given repeated injections of aluminum or saline vehicle [20].
The current results are also consistent with measurements of
bone aluminum using flameless atomic absorption spectroscopy
in intact and TPTX rats given aluminum parenterally [26].
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Table 4. Assessment of the independent effects of thyroparathyroidectomy and aluminum administration on bone and matrix appositiona
Bone
-AL
apposition rateb
+AL
Matrix apposition rateb
-AL +AL
+PTH
—PTH
(20.8%)
5.48
0.70
4.34
0.80
(374%)C
3.43
0.56
2.70
1.01
(37.8%)
(21.3%)
+PTH
—PTH
(20.8%)
(394%)
5.49 3.33
0.73 0.60
4.35 2.27
0.85 1.03
(47.8%)
(31.8%)
—AL
vs.
+AL
P < 0.0001
+PTH
vs.
-PTH
P < 0.005
Interaction'
NS
—AL
vs.
+AL
P < 0.0001
+PTH
vs.
-PTH
P < 0.0005
Interaction"
P < 0.05
a Probabilities determined by factorial analysis of variance. Values are means one SD
b Units are mIday
C Percentage values represent differences between adjacent cells
A measure of the independence of the effects of aluminum loading and parathyroid hormone on bone and matrix apposition; the null hypothesis
of independence is rejected for matrix apposition
The deposition of aluminum in bone is consistently associ-
ated with reductions in the formation of mineralized bone in
man and in experimental animals, but the mechanism respon-
sible for this disturbance remains uncertain [6, 7, 9—12, 17, 18].
Several studies have confirmed an inverse relationship between
the aluminum content of bone and the rate of bone formation in
aluminum—associated bone disease [6—i 11. Such findings sug-
gest that the accumulation of aluminum in skeletal tissue
directly impairs the formation of mineralized bone and/or
suppresses the synthesis of bone collagen [17, 18]. However,
reductions in the secretion of PTH during aluminum loading
could also contribute to a state of low bone formation and
turnover in aluminum—related bone disease by modifying either
the number or the function of bone cells, particularly osteo-
blasts.
Using an amino-terminal assay, Robertson et al reported
lower values for serum iPTH in rats given repeated injections of
aluminum for eleven weeks than in control animals [10]; con-
current evidence of reductions in the number of osteoblasts was
also presented [10]. Such observations are consistent with
clinical data which indicate that the basal levels of PTH in
serum are frequently inappropriately low in chronic dialysis
patients with aluminum—related bone disease [12], and that the
secretion of PTH in response to hypocalcemia is diminished in
hemodialysis patients with aluminum associated osteomalacia
[13, 14]. Moreover, aluminum can deposit in parathyroid tissue
[27], and there are in vitro data which indicate that aluminum
reduces the secretion of PTH from dispersed bovine parathy-
roid—cells in tissue culture [28].
If aluminum induced reductions in the secretion of PTH were
a major determinant of the decrease in bone formation in
animals given parenteral aluminum, then TPTX would be
expected to modify or eliminate this response. In the current
study, bone formation fell from control values both in intact and
in TPTX animals given aluminum. These findings fail to support
a role for aluminum induced reductions in the secretion of PTH
as a primary mediator of low bone formation during short—term
aluminum loading. In previous reports in the rat and in the dog,
bone formation also decreased in the absence of changes in
basal serum PTH levels and without evidence of reductions in
the secretion of PTH during hypocalcemic stimuli [11, 17].
Thus, aluminum impairs the formation of bone by a PTH
independent mechanism.
In addition, bone formation was reduced to a similar degree
in intact and in TPTX animals given aluminum. Thyroparathy-
roidectomy did not aggravate the adverse effect of aluminum
loading on mineralized bone formation, and the low rate of bone
formation in TPTX rats did not promote the skeletal uptake of
aluminum. These findings indicate that persistently low levels
of PTH in serum do not enhance the effect of aluminum to
suppress mineralized bone formation during short—term alumi-
num administration. The rate of accumulation of aluminum in
bone may increase during prolonged aluminum loading as a
consequence of the state of low bone formation and turnover
following parathyroidectomy, and the current short—term ex-
perimental results do not exclude this possibility [15, 16]. Also,
abrupt changes in the metabolism of bone and in the uptake of
aluminum into bone could occur immediately after parathyroid-
ectomy under circumstances where hyperparathyroid bone
disease was sustained before parathyroid gland removal, and
this was not the case in the current experiment. Nevertheless,
hypoparathyroidism is not essential for the early changes in
bone aluminum deposition and bone formation in the aplastic
lesion of experimental, aluminum—related bone disease.
The formation of mineralized bone decreased in both alumi-
num treated groups, but neither demonstrated histologic
changes by light microscopy of overt osteomalacia with wid-
ened osteoid seams and increases in osteoid area. Indeed, in
TPTX-AL, the area of osteoid and the width of osteoid seams
diminished from control values. These alterations in bone
histology are consistent with findings in the aplastic lesion of
renal osteodystrophy [29—31] as well as in other conditions of
low bone formation and turnover, such as diabetes [32, 33]. In
order for such histologic changes to develop, the rate of
synthesis of osteoid must be reduced to a greater degree than
the rate of mineralized bone formation; this disturbance results
in lower values for osteoid area and osteoid seam width [33].
Using the technique of double tetracycline labeling, estimates
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of the rate of production of osteoid, that is, bone matrix, can be
made for trabecular bone only after serial bone biopsies, and
these were not done at the epiphysis of the proximal tibia.
However, measurements of matrix formation at the periosteal
surface of cortical bone were completed using techniques
described previously [17, 18, 33, 34].
The linear rate of mineralized bone apposition and the linear
rate of matrix apposition at the tibial cortex were each dimin-
ished in intact rats given aluminum (Table 4). Similar findings
were documented in TPTX aluminum—treated animals (Table
4). When the effect of TPTX was controlled using factorial
analysis of variance, there was an independent inhibitory effect
of aluminum on both bone and matrix apposition in aluminum
treated animals (Table 4). However, a positive interaction
between the effect of TPTX and the effect of aluminum admin-
istration was established only for matrix apposition; no such
relationship was determined for mineralized bone apposition
using factorial analysis of variance (Table 4). Thus, the produc-
tion of bone collagen, or osteoid, was impaired to a greater
extent than the formation of mineralized bone during short—
term aluminum administration in TPTX animals. This distur-
bance in collagen synthesis accounts for the development of
aplastic skeletal changes in TPTX-AL.
In conclusion, aluminum administration substantially reduces
the synthesis of bone collagen, and low serum levels of PTH
can aggravate this disturbance. The aplastic lesion of aluminum—
related bone disease is due to an early, adverse effect of
aluminum loading on the formation of osteoid. Mineralized
bone formation is impaired during parenteral aluminum admin-
istration, but this disturbance is mediated by a PTH indepen-
dent mechanism. Persistently—low serum levels of PTH do not
enhance the skeletal uptake of aluminum during short—
term aluminum loading. The data suggest that local tissue
disturbances associated with the accumulation of aluminum in
bone rather than alterations in the secretion of PTH are the
major determinant of impaired bone formation in aluminum—re-
lated bone disease.
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